Brief: Idorsia Posts Phase 3 Study Results Of Daridorexant
05/01/2026 16:49
Jan 5 (Reuters) - IDORSIA LTD IDIA.S: PHASE 3 STUDY OF DARIDOREXANT SHOWS THAT 50 MG IMPROVED BOTH SLEEP AND DAYTIME FUNCTIONING COMPARED TO PLACEBO IN WOMEN DURING MENOPAUSAL TRANSITION AGE Source text: ID:nGNXb741GK Further company coverage: IDIA.S (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))